个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊

作者：
Hu Danrong[1,2] * ; Li Yicong[1] * ; Li Ran[1,2] ; Wang Meng[1] ; Zhou Kai[3] ; He Chengqi[1,2] ; Wei Quan[1,2] ; Qian Zhiyong[1] ;
机构： [1]Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. [2]Key Laboratory of Rehabilitation Medicine in Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China. [3]Department of Orthopedics, West China Hospital, Sichuan University, Chengdu 610041, China.
出处：
DOI： 10.1016/j.apsb.2024.10.015
ISSN：

摘要：
Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) have garnered significant attention in cancer research because of their potential for precise spatiotemporal drug release tailored to high ROS levels within tumors. Despite the challenges posed by ROS distribution heterogeneity and endogenous supply constraints, this review highlights the strategic alliance of ROS-responsive DDSs with photodynamic therapy (PDT), enabling selective drug delivery and leveraging PDT-induced ROS for enhanced therapeutic efficacy. This review delves into the biological importance of ROS in cancer progression and treatment. We elucidate in detail the operational mechanisms of ROS-responsive linkers, including thioether, thioketal, selenide, diselencide, telluride and aryl boronic acids/esters, as well as the latest developments in ROS-responsive nanomedicines that integrate with PDT strategies. These insights are intended to inspire the design of innovative ROS-responsive nanocarriers for enhanced cancer PDT.© 2024 The Authors.

基金：
This work was financially supported by the National Natural Science Funds (NSFC 32001003, U21A20417 and 31930067, China) and 1$3$5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18002, China). We also thank the support of the Natural Science Foundation of Sichuan Province (2022NSFSC1282, China).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 药学
第一作者：
第一作者机构： [1]Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. [2]Key Laboratory of Rehabilitation Medicine in Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Hu Danrong,Li Yicong,Li Ran,et al.Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer[J].Acta Pharmaceutica Sinica B.2024,14(12):5106-5131.doi:10.1016/j.apsb.2024.10.015.
APA：
Hu Danrong,Li Yicong,Li Ran,Wang Meng,Zhou Kai...&Qian Zhiyong.(2024).Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.Acta Pharmaceutica Sinica B,14,(12)
MLA：
Hu Danrong,et al."Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer".Acta Pharmaceutica Sinica B 14..12(2024):5106-5131

资源点击量：53684 今日访问量：0 总访问量：4604 更新日期：2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号